tradingkey.logo

Exact Sciences Corp

EXAS
查看詳細走勢圖
101.500USD
+0.140+0.14%
收盤 12/12, 16:00美東報價延遲15分鐘
19.23B總市值
虧損本益比TTM

Exact Sciences Corp

101.500
+0.140+0.14%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.14%

5天

+0.44%

1月

+49.82%

6月

+89.65%

今年開始到現在

+80.64%

1年

+65.71%

查看詳細走勢圖

TradingKey Exact Sciences Corp股票評分

單位: USD 更新時間: 2025-12-12

操作建議

Exact Sciences Corp當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名16/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價98.67。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Exact Sciences Corp評分

相關信息

行業排名
16 / 404
全市場排名
85 / 4592
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 23 分析師
持有
評級
98.673
目標均價
-2.27%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Exact Sciences Corp亮點

亮點風險
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
業績高增長
公司營業收入穩步增長,連續3年增長32.37%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入2.76B美元
估值合理
公司最新PE估值-19.01,處於3年歷史合理位
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉176.61K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.52

Exact Sciences Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Exact Sciences Corp簡介

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
公司代碼EXAS
公司Exact Sciences Corp
CEOConroy (Kevin T)
網址https://www.exactsciences.com/

常見問題

Exact Sciences Corp(EXAS)的當前股價是多少?

Exact Sciences Corp(EXAS)的當前股價是 101.500。

Exact Sciences Corp 的股票代碼是什麼?

Exact Sciences Corp的股票代碼是EXAS。

Exact Sciences Corp股票的52週最高點是多少?

Exact Sciences Corp股票的52週最高點是101.950。

Exact Sciences Corp股票的52週最低點是多少?

Exact Sciences Corp股票的52週最低點是38.812。

Exact Sciences Corp的市值是多少?

Exact Sciences Corp的市值是19.23B。

Exact Sciences Corp的淨利潤是多少?

Exact Sciences Corp的淨利潤為-1.03B。

現在Exact Sciences Corp(EXAS)的股票是買入、持有還是賣出?

根據分析師評級,Exact Sciences Corp(EXAS)的總體評級為持有,目標價格為98.673。

Exact Sciences Corp(EXAS)股票的每股收益(EPS TTM)是多少

Exact Sciences Corp(EXAS)股票的每股收益(EPS TTM)是-5.340。
KeyAI